Noninvasive ventilation acutely modifies heart rate variability in chronic obstructive pulmonary disease patients  by Borghi-Silva, Audrey et al.
Respiratory Medicine (2008) 102, 1117e1123ava i lab le at www.sc ienced i rec t . com
journa l homepage : www.e lsev ier . com/ loca te / rmedNoninvasive ventilation acutely modifies heart
rate variability in chronic obstructive
pulmonary disease patientsAudrey Borghi-Silva a,*, Michel Silva Reis a, Renata Gonc¸alves Mendes a,
Camila Bianca Falasco Pantoni a, Rodrigo Polaquini Simo˜es a,
Luis Eduardo Barreto Martins b, Aparecida Maria Catai aa Cardiopulmonary Physiotherapy Laboratory, Nucleus of Research in Physical Exercise, Department of Physiotherapy,
Federal University of Sa˜o Carlos, UFSCar, Rodovia Washington Luis, KM 235, Monjolinho, CEP: 13565-905,
Sa˜o Carlos, SP, Brazil
b Laboratory of Exercise Physiology, Faculty of Physical Education, Estadual University of Campinas,
Campinas, SP, Brazil
Received 30 November 2007; accepted 16 March 2008





Heart rate variability* Corresponding author. Tel.: þ55 16
E-mail address: audrey@power.ufs
0954-6111/$ - see front matter ª 200
doi:10.1016/j.rmed.2008.03.016Summary
Objective: The purpose of present study was to evaluate the acute effects of bi-level positive
airway pressure (BiPAP) on heart rate variability (HRV) of stable chronic obstructive pulmonary
disease patients (COPD).
Methods: Nineteen males with COPD (69 8 years and with forced expiratory volume in 1 s
<50% of predicted) and eight healthy sedentary age-matched (69 years) males in the control
group (CG) were evaluated during two conditions of controlled respiratory rate: spontaneous
breathing (SB) and BiPAP (inspiratory and expiratory levels between 12e14 cmH2O and 4e
6 cmH2O, respectively). Peripheral oxygen saturation (SpO2), end-tidal of carbon dioxide
(ETCO2), systolic blood pressure (SBP) and ReR interval were obtained. HRV was analyzed by
time (RMSSD and SDNN index) and frequency domains (high frequency e HF, low frequency e
LF and HF/LF ratio).
Results: Significant reduction of ETCO2 and SBP in both groups and increase of SpO2 in COPD
group was observed during BiPAP ventilation (p< 0.05). During spontaneous breathing, patients
with COPD presented lower values of LF, LF/HF and higher values of HF when compared to CG
(p< 0.05). However, HF was significantly reduced and LF increased during BiPAP ventilation
(58 19e48 15 and 41 19e52 15un, respectively) in COPD group. Significant correlations
between delta BiPAP-SB (D) ETCO2 and DHF were found (rZ 0.89).3351 8705; fax: þ55 16 3361 2081.
car.br (A. Borghi-Silva).
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1118 A. Borghi-Silva et al.Conclusions: Sympathetic and parasympathetic neural control of heart rate is altered in COPD
patients and that BiPAP acutely improves ventilation, enhances sympathetic response and
decreases vagal tonus. The improvement of ventilation caused by BiPAP was associated with re-
duced cardiac vagal activity in stable moderate-to-severe COPD patients.
ª 2008 Elsevier Ltd. All rights reserved.Introduction
Several studies have shown that noninvasive positive
pressure ventilation (NPPV) has been successfully used to
reduce the respiratory work, the need for intubation,
respiratory complications, mortality and morbidity during
acute exacerbations of respiratory failure.1e3 In stable
chronic obstructive pulmonary disease (COPD), in particu-
lar, NPPV administered in acute respiratory failure has re-
duced inspiratory effort,4 dyspnea and improved exercise
tolerance.5,6 For this reason, some modes of NPPV have
been tested as an adjunct therapy during short-term inter-
ventions.7e9
However, reports describing the effects of NPPV on
hemodynamic and neural control in acute conditions have
been both limited and contradictory.10e12 Bi-level positive
airway pressure (BiPAP) has been shown to be effective in
improving ventilation and does not create significant hemo-
dynamic instability.11 Also of note, Skyba et al.13 have dem-
onstrated that BiPAP may cause improvements in the neural
control of heart rate by reducing blood pressure in exacer-
bated COPD patients.
It remains unclear whether this same effect occurs on
neural control of heart rate, as evaluated by heart rate
variability (HRV), during acute BiPAP in stable COPD
patients. These aspects are important since HRV has been
used to reflect not only cardiac autonomic nervous activity,
but also the severity of cardiac and non-cardiac diseas-
es.14e17 In addition, the evaluation of HRV may contribute
to the better understanding of mechanisms, indicators, ef-
fectiveness and safety during the different short18e20 and
long-term21e24 interventions in many clinical conditions.
Thus, the aim of this study was to noninvasively evaluate
neural control of heart rate by time (TD) and frequency do-
main (FD) analysis in patients with stable moderate-to-
severe COPD during spontaneous breathing and BiPAP
ventilation and also examine the relationship between the




This study included nineteen male patients with COPD
(69 8 years) and eight healthy male control individuals
of similar age (68 5 years). The participants signed an
agreement of informed consent in order to participate
and this study was approved by the Ethics Committee of
the Institution.
The healthy subjects were in good health, presented no
evidence of disease based on clinical and physical exami-
nation and laboratory tests that included a standardelectrocardiogram (ECG), clinical biochemical screening
tests and were not taking any medication. All healthy
subjects had sedentary life-styles and were non-smokers.
The COPD patients had sedentary life-styles, had
stopped smoking at least three months prior to enrollment
in the study and had been in clinically stable condition
without exacerbations for at least one month. Additionally,
the COPD patients presented partial pressure of arterial
carbon dioxide (PaCO2) <60 mmHg during breathing of
room air and PaO2 <70 mmHg, forced expiratory volume
in 1 s (FEV1) <50% of predicted and forced vital capacity
to FEV1 <70% of predicted. The chest X-rays in COPD
patients presented hyperinflation and patients frequently
reported dyspnea symptoms during physical activity. All
bronchodilators, such as B2-agonists, xanthene derivatives
and steroid treatments were suspended 24 h before the ini-
tiation of the study. None of the patients had been using
anti-arrhythmic medications.
Patients with arterial hypertension, congestive heart
failure, respiratory infection within the last four weeks,
diabetes mellitus, ischemic heart disease and elevated
natriuretic peptide levels were excluded. All subjects
were evaluated during the same time of day in order to
avoid differences in response due to circadian changes, at
an experimental room temperature of 22 C with relative
air humidity between 50 and 60%. Subjects were oriented
to avoid caffeinated and alcoholic beverages and not to
perform exercise on the day before the tests.
Pulmonary function tests
All patients underwent spirometry to determine FEV1, FVC
and maximal voluntary ventilation (MVV), in accordance
with ATS recommendations.25 The values obtained were
compared to the predicted normal values of Knudson
et al.26 Spirometry was performed using the Vitalograph
Hand-Held 2021 instrument (Ennis, Ireland).
Experimental protocol
The vagal and sympathetic activity in patients with COPD
and healthy subjects were compared at baseline (sponta-
neous breathing) and during BiPAP. After adaptation to the
environment, the study protocol consisted of two experi-
mental conditions.
Spontaneous breathing (SB)
On arrival at the laboratory, the subjects were seated
comfortably for approximately 15 min, while peripheral ox-
ygen saturation (Nonin 8500A Plymouth, USA) was moni-
tored. The subjects breathed via a tight-fitting nasal mask
(Respironics, Murrysville, PA) connected to a capnometer
(carbon dioxide monitor BCI-1050, Waukesha, USA). The
Effect of BiPAP on heart rate variability in COPD 1119subjects were oriented to breathe through for 10 min and
the peripheral oxygen saturation (SpO2), respiratory rate
and end-tidal of carbon dioxide (ETCO2) were monitored.
BiPAP ventilation
Room air was fed to a portable NPPV (BiPAP model S:
Respironics; Murrysville, PA) and the BiPAP was applied via
a tight-fitting nasal mask (Respironics, Murrysville, PA) at
minimum internal volume. The NPPV was attached to the
nasal mask using identical ventilation circuits that incorpo-
rated a whisper swivel II expiratory valve (Respironics,
Inc.). The inspiratory positive airway pressure (IPAP) was
set at 6 cmH2O and was increased gradually at 2 cmH2O
per minute to a maximum of 14 cmH2O (as high as possible
based on patient’s tolerance). The expiratory positive air-
way pressure (EPAP) was set at 3 cmH2O and was increased
gradually at 1 cmH2O per minute to a maximum of 6 cmH2O.
The gradual increases in both the inspiratory and expiratory
pressures were aimed at increasing comfort and compli-
ance in volunteers. These values were set in a rather arbi-
trary manner and were designed to provide what would be
considered by most as mild expiratory pressure and moder-
ate inspiratory pressure support. The capnometer was
attached to the orifice in the nasal mask (BCI-1050, Wauke-
sha, USA).
After this, the subjects were oriented to relax, breathe
calmly and maintain a respiratory rate similar to sponta-
neous breathing during BiPAP ventilation, which was visu-
ally displayed by the capnometer, located in clear view and
directly in front of the subjects. There was an adaptation
period for patients followed by a BiPAP application of
approximately 15 min.
Physiological measurements
SpO2 was continuously monitored by portable pulse oxime-
try. ETCO2 and the respiratory rate were obtained by means
of a capnometer reading that was recorded each minute
and at the end of the experimental procedures. The systolic
blood pressure (SBP) and diastolic blood pressure were
measured by indirect method with sphygmomanometer
and stethoscope and were analyzed at baseline and for
the last 30 s of the protocol with and without BiPAP applica-
tion. HRV was registered using the Polar system. An elastic
belt (Polar T31 transmitter, Polar Electro, Kempele, Fin-
land) was attached to the chest of the volunteers at the
level of the lower third of the sternum. The belt contains
a stable case with heart rate electrodes, electronic pro-
cessing unit, and an electromagnetic field transmitter.
The heart rate signals are continuously transmitted to the
Polar Advantage receiver unit via an electromagnetic field.
The digitally coded ReR interval length is continuously
transferred to the Polar Precision Performance software
that in turn displays a heart rate tachogram on the moni-
tor.27 In addition, the patients were monitored using a tho-
racic MC5 lead (cardiac monitor Ecafix TC500, Sa˜o Paulo,
SP, Brazil), with the yellow lead placed on the left and right
of 5th intercostal space, the red lead at manubrium ster-
num and the black lead (neutral) in the right 5th intercostal
space to simultaneously obtain the heart rate in order to
evaluate the signals on the monitor for exclusion ofmovement artifacts and ectopic beats prior to the HRV
analysis. The data of ReR intervals were obtained in short
recordings (10 min) for each period.
HRV analysis
The sections selected for HRV analysis during SB and BiPAP
were the most stable sections containing 256 points within
the 10 min, excluding the final 30 s (to avoid possible influ-
ences by the blood pressure measurement). HRV was ana-
lyzed by time and frequency domain methods by
a specific routine developed in Matlab V. 6.1 software. In
the time domain analysis, the standard deviation of the
normal ReR intervals (SDNN), that is the square root of var-
iance; and the square root of the mean sum of the squares
of the difference between adjacent normal ReR interval
within a given time minus one (RMSSD)14,15 were analyzed.
In the frequency domain analysis, the power spectral
components were reported at low (0.04e0.15 Hz) and high
(0.15e0.4 Hz) frequencies using the Fast Fourier Transform.
The data, calculated by the total power less the power of
the component with a frequency range between 0 and
0.03 Hz, i.e., at very low frequency,14,16 were expressed
in absolute and normalized units and low/high frequency
ratios.16
Statistical analysis
Due to the Gaussian distribution and/or homogeneity of
variance in variable values, parametric tests were selected
for statistical analysis. Thus, the unpaired Student t-test
was employed to compare data of physiologic parameters
and HRV measurements between groups and Paired t-test
were used for intragroup comparisons. The relationship be-
tween delta BiPAP-SB (D) of HRV data collected during Bi-
PAP and spontaneous breathing with delta physiological
measurement was assessed using Pearson’s correlation.
The level of significance was set at 5%. The analysis was
carried out using the Statistica for Windows software re-
lease 5.1 StatSoft, Inc.
Results
Table 1 shows the mean values of demographics, anthropo-
metrics and pulmonary function for COPD and control
groups. Patients presented moderate to severe airway ob-
struction and seven patients received domiciliary oxygen.
No significant differences between groups in relation to
demographics and anthropometrics were found. The COPD
patients presented lower values in FVC and FEV1 than the
control group (p< 0.05).
Physiologic parameters
Table 2 shows the physiologic parameters measured in con-
trol and COPD groups. No significant differences were ob-
served in respiratory rate between SB and BiPAP
application. However, there was a significant reduction in
SBP during BiPAP application in both groups. The SpO2 was
lower in the COPD patients than control group for both the
SB and BiPAP conditions. Significant increase of SpO2 was
Table 1 Demographics, anthropometrics and baseline







Age (yrs.) 69 8 68 5 NS
Height (cm) 166 0.05 168 0.04 NS
Weight (kg) 68 13 69 9 NS
BMI (kg/m2) 24.6 2.9 24.6 3 NS
Pulmonary function
FEV1 (%) 35 9 103 17 <0.0001
FVC (%) 64 17 103 18 <0.0002
FEV1/FVC 44 9 99 8 <0.0001
PaO2 (mmHg) 61 8 e e
PaCO2 (mmHg) 44 6 e e
SaO2 (%) 91 4 e e
Inspiratory level (cmH2O 14 2 14 2 NS
Expiratory level (cmH2O) 5 1 5 1 NS
Values are mean SD.
NS: not significant; BMI: body mass index; FEV1: forced expira-
tory volume in 1 s; FVC: forced vital capacity; PaO2: arterial ox-
ygen tension; PaCO2: arterial carbon dioxide tension; and SaO2:
arterial oxygen saturation (arterial blood gases measurements
were performed with the patients at rest and breathing room
air).
1120 A. Borghi-Silva et al.observed during BiPAP only in COPD patients. In relation to
ETCO2, significant reduction was observed during BiPAP in
both groups (p< 0.05).
Time and frequency domain index of HRV
Table 3 shows the HRV values in time and frequency domain
during SB and BiPAP. In the time domain analysis, the intra-
group comparisons showed significant differences only in
the SDNN index for control group, where we found lower
values during BiPAP. No differences between COPD and
the control group were found in RMSSD and SDNN indexes
during SB and BiPAP application.Table 2 Physiologic parameters for COPD and control






SB BiPAP SB BiPAP
RR (bpm) 15 5 14 5 12 3 13 2
SBP (mmHg) 122 13 114 11a 118 10 110 5a
SpO2 (%) 90 3 93 2a 97 1b 97 1b
ETCO2 (mmHg) 42 5 36 4a 39 4 35 5a
Values are mean SD.
SB: spontaneous breathing; BiPAP: bi-level positive airway pres-
sure; RR: respiratory rate; SBP: systolic blood pressure; DBP: di-
astolic blood pressure; SpO2: peripheral oxygen saturation; and
ETCO2: end-tidal of carbon dioxide.
a Significant differences between SB vs. BiPAP application
(p< 0.05).
b Significant differences between COPD vs. control (p< 0.05).In frequency domain analysis, significant reductions in
HF as well as increases in LF were found during BiPAP
ventilation of the patients. In contrast, BiPAP ventilation
did not alter HRV in the control group. Additionally, during
spontaneous breathing or BiPAP ventilation the control
group presented higher values in the LF band and lower
values in the HF band (un) than patients with COPD.
Fig. 1 shows the positive and significant correlation be-
tween DHF with DETCO2 (rZ 0.89). However, no correla-
tions were found between DHF and DLF to DSpO2
(rZ0.37 and rZ 0.22, p> 0.05, respectively).
Discussion
The principal findings in this study were significant alter-
ations in autonomic modulation of heart rate with reduced
sympathetic and increased parasympathetic activity in
COPD patients when compared to the age-matched control
group. BiPAP ventilation acutely caused variations of HRV in
COPD patients with improvement of sympathetic and
reduction of parasympathetic response. In addition, the
reduction of ETCO2 is associated with decrease of vagal ac-
tivity in these patients.
Physiologic effects of BiPAP in COPD
and healthy subjects
The physiologic parameters were modified in a similar way
during the application of the BiPAP in patients with COPD
and the control group (Table 2). In addition, the pressoric
levels applied had been strong enough to reduce ETCO2
and improve SpO2 in COPD patients.
The respiratory rate as well as ETCO2 can modulate
HRV.28 In our study the respiratory rate remained un-
changed throughout both conditions (spontaneous breath-
ing and BiPAP), but ETCO2 was reduced in both groups.
The administration of NPPV may have increased tidal vol-
ume and minute ventilation and thus reduced the levels
of ETCO2.
In regard to SBP, the reduction observed during BiPAP in
both the COPD and control groups can be explained as the
effect of positive airway pressure, which produces a re-
duction of the venous return and, consequently, of stroke
volume, cardiac output and systolic blood pressure.10,13,29
In this study systolic pressure showed no effect on and
was not associated to modifications in HRV. Although Skyba
et al.13 have shown that a significant reduction in SBP was
achieved due to HRV alteration during the same magnitude
NPPV application as in our study (10 mmHg), the patients in
their study differed from the present study in two charac-
teristics: the condition of the patients was exacerbated,
and secondly, mean systolic blood pressure baseline values
were higher (147 mmHg).
Neural control of heart rate between COPD and
healthy subjects
In our study we observed that stable moderate-to-severe
COPD presented important alterations in parasympathetic
and sympathetic neural activity when compared to the
control group. These results corroborated other previous
Table 3 Heart rate variability in time and frequency domain during spontaneous breathing and BiPAP in COPD and control
groups
COPD (nZ 19) Control (nZ 8)
SB BiPAP SB BiPAP
HR (bpm) 78 11 79 11 67 6 70 6
Time domain
RMSSD (ms) 13.6 7.3 13.5 8.0 15.1 6.3 12.3 6.5
SDNN (ms) 22.7 13.0 26.3 14.8 27.5 13.8 21.9 8.6a
Frequency domain
LF (ms2) 1602 1133 2203 1300a 6274 2640b 5516 1739b
HF (ms2) 2736 1749 2443 1209 4162 2983 2596 818
LF (un) 41.4 18.6 52 14.9a 68.8 17.8b 75.3 9.5b
HF (un) 58.5 18.6 47.9 14.9a 31.2 17.7b 24.6 9.5b
LF/HF 0.9 0.7 1.3 0.9a 3.6 2.6b 3.7 2.3b
Values are mean SD.
SB: spontaneous breathing; BiPAP: bi-level positive airway pressure; TD: time domain; FD: frequency domain; HR: heart rate; RMSSD:
square root of mean of the squared differences between adjacent ReR intervals; SDNN: standard deviation of the normal interval;
LF (nu): low frequency in normalized units; HF (nu): high frequency in normalized units; and LF/HF: low frequency/high frequency ratio.
a Significant differences between SB vs. BiPAP application (p< 0.05).
b Significant differences between COPD vs. Control (p< 0.05).
Effect of BiPAP on heart rate variability in COPD 1121studies which described that normoxemic as well as
hypoxemic patients with COPD appear to have impaired
cardiac autonomic modulation at rest, as reflected in
reduced HRV.18,30e33
In contrast to our study, Heindl et al.33 have inferred
that COPD patients present an increase in sympathetic ac-
tivity. However, the subjects in the study by Heindl
et al.33 differed greatly in clinical condition, age and level
of hypoxemia from the subjects in the present study. The
COPD patients in the present study were outpatients in clin-
ically stable condition while the patients studied by Heindl
et al.33 were hospitalized and in exacerbated condition.
Secondly, the age of the patients in Heindl et al. study
was 17e68 years while our patients were all older subjects
(median ages of 70 years). The participants in the study by
Heindl et al.33 were also more hypoxemic than the subjects
in the present study.Figure 1 Delta ETCO2 correlated significantly with Delta HF
(un) in COPD patients.In addition, some authors30 have observed that COPD pa-
tients present an increase in parasympathetic activity that
leads to reduction in FEV1 and the bronchioconstriction typ-
ically seen in these patients. In our study, we found ele-
vated vagal and reduced sympathetic activity in these
patients (Table 3), in accordance with Volterrani et al.30
Neural control of heart rate during BiPAP
ventilation in COPD
In the present study, we found significant modifications in
HRV during BiPAP ventilation with a reduction in vagal
overactivity in COPD patients. In addition, the variation of
ETCO2 significantly correlated with variation of HF band
(Fig. 1). We speculate that the improvement of minute ven-
tilation (due to increase of tidal volume) during BiPAP venti-
lation might be responsible for these results. In this context,
Po¨yho¨nen et al.28 found that arterial CO2 strongly modulates
HRV by affecting the firing rate of the autonomic nervous sys-
tem to the respiratory muscles and cardiorespiratory control
network, which in turn influences the HRV spectrum.
The hypoxemia is another factor that can alter HRV. In
our study, BiPAP ventilation was capable of improving the
oxygenation of these patients without oxygen supplemen-
tation. However, the delta of oxygen saturation was not
associated to alterations in the autonomic control of heart
rate in our patients. Although Chen et al.18 have demon-
strated that chronic hypoxemia can lead to damage of car-
diac control from the increase of vagal activity and the
reduction of sympathetic activity in stable COPD patients;
the use of BiPAP ventilation, nonetheless, still reduces re-
spiratory work, improve expiratory time and avoids airway
collapse.
Methodological considerations
This is the first study that compared the influence of BiPAP
ventilation on HRV in patients with stable COPD and the
1122 A. Borghi-Silva et al.responses of HRV found in the present study differ from
other authors on NPPV results due to exposition time,
pressoric level and ventilatory mode and stability or
exacerbation of disease.
In relation to time, long-term CPAP administration may
reduce sympathetic activity in obstructive sleep apnea
syndrome.23,24 In addition, Sin et al.34 found that NPPV,
applied nocturnally over three months, improved HRV, re-
duced circulating natriuretic peptide levels, and enhanced
the functional performance of patients with advanced but
stable COPD.
Another aspect that differed in our results was the
modality of NPPV and the pressoric levels used in the
present study. BiPAP delivers a positive pressure assist
(inspiratory positive airway pressure e IPAP) that signifi-
cantly reduces the work of breathing. Each patient breath
is triggered above a mild baseline expiratory positive
pressure that maintains alveolar stability.35 While some au-
thors have shown that BiPAP does not significantly affect
central hemodynamic control in comparison to CPAP be-
cause the expiratory positive pressure levels are lower,11
it must be noted that the influence of positive airway pres-
sure on central hemodynamic control is related to the mag-
nitude of inspiratory pressure levels.
In patients with exacerbations of COPD, Skyba et al.13
demonstrated that 1 h of BiPAP resulted in significant re-
duction of sympathetic activity. Sympathetic response is
frequently seen in exacerbations of many chronic diseases.
However, Skyba et al.13 did not control a factor that can be
responsible for improved HRV: the reduction of respiratory
rate. Noninvasive ventilation can reduce respiratory work
by affecting tidal volume and respiratory rate to improve
HRV in exacerbated patients.
Our results showed that a moderate inspiratory positive
airway pressure combined with a mild expiratory positive
pressure application titrated within the tolerance of our
patients during brief interventions could produce an im-
provement in ventilation, promote airway stability and
thereby can reduce airway vagal activity. Volterrani
et al.30 demonstrated that bronchoconstriction seen in
COPD and asthma patients (due to reduced FEV1) could
lead to an increase in parasympathetic tone. In this con-
text, strategies that could provide greater airway stability
and prevent alveolar collapse could reduce the parasympa-
thetic tonus and thus reduce the air trapping. These issues
are important because the application of bi-level NPPV is
being widely used in short-term interventions6e9 such as re-
spiratory therapy sessions and our findings are an important
verification that supports this treatment.Study limitations
The main drawback of our study was the impossibility of
controlling tidal volume and other parameters of respiratory
work. Thus, the inferences of our study were speculative. In
addition, a small number of patients were recruited, a fact
possibly due to the strict criteria for patient inclusion and
the severity of the disease of the patients evaluated. Finally,
our results are short-term and restricted to patients with
stable COPD. Therefore, studies about the effects of non-
invasive ventilation during long-term treatment arenecessary and the different treatment pressoric levels
must be studied because they are a determining factor of
changes in the heart rate variability of these patients.
Conclusions
In summary, sympathetic and parasympathetic neural
control of heart rate is altered in COPD patients. Moreover,
BiPAP acutely improves ventilation, sympathetic response
and decreases vagal response. The improvement of venti-
lation caused by BiPAP is associated with the reduction of
cardiac vagal activity in stable moderate-to-severe COPD
patients.
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